Sunitinib is used as a targeted therapy and a receptor protein-tyrosine kinase inhibitor for advanced renal cell cancer and gastrointensinal stromal tumor (GIST). Sunitinib is marketed under the name Sutent. The drug may also be used in combination with other chemotherapy drugs or for the treatment of other cancers.
Related categories 1
Provides drug description, side effects, and how the therapy works.
Medication description and FDA approved drug information including side effects, interactions and patient labeling.
Sutent (sunitinib malate)
Official site and information about using the drug in treatment for advanced renal cell carcinoma and gastrointestinal stromal tumor (GIST).
Description of targeted therapy drug includes indications for therapy and links.
Last update:April 20, 2008 at 0:29:41 UTC